UTRS

Minerva Surgical Inc

UTRS, USA

Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.

https://minervasurgical.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
UTRS
stock
UTRS

T2 Biosystems (NASDAQ:TTOO) versus Minerva Surgical (NASDAQ:UTRS) Head-To-Head Review Defense World

Read more →
UTRS
stock
UTRS

Look For Ubiquiti UniFi Travel Router Restocks Resell Calendar

Read more →

Showing 2 of 8

Analyst Ratings & Sentiment

(Last Updated 2023-09-30)

Rating:

BUY

Target Price:

$3

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2023-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.00

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-35.45 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-9.87 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-42.72 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

2.59

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.01% of the total shares of Minerva Surgical Inc

1.

Northern Trust Extended Eq Market Idx

(0.0025%)

since

2023/12/31

2.

NT Ext Equity Mkt Idx Fd - L

(0.0025%)

since

2023/12/31

5.

Cubist Systematic Strategies, LLC

(0%)

since

2023/09/30

6.

UBS Group AG

(0%)

since

2023/09/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2023-09-30

EPS Actual

-0.81

EPS Estimate

-1

EPS Difference

0.19

Surprise Percent

19%

Investing Fit Scorecard

(Last Updated 2023-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(1)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(1)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2023-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2023-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2023-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.